Gastrointestinal stromal tumors
Conditions
Interventions
Group 1 :elemene combined with imatinib
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient is 18-75 years old, male or female, and signs an informed consent form; 2. Patients with gastrointestinal stromal tumors confirmed by histopathology; 3. There are measurable lesions or observable imaging data such as CT and MRI; 4. First-line imatinib treatment failed; 5. KPS score >= 60; 6. The estimated survival time is >= 3 months; 7. Hemogram: RBC >= 3.0 x 10^12/L, WBC >= 3.5 x 10^9/L, ANC >= 1.5 x 10^9/L, PLT >= 100 x 10^9/L, HB >= 90 g/L; 8. Renal function: Cr <= 1.2 x UNL (upper limit of normal value); 9. Liver function: total bilirubin <= 1.5 x UNL; ALT, AST <= 1.5 x UNL.
Exclusion criteria
Exclusion criteria: 1. Allergic constitution, those who are known to be allergic to the components of this medicine; 2. Patients with high fever and acute infection; 3. Patients with progressive bleeding; 4. Important organs have primary diseases; 5. Participated in any clinical trial of research drugs within 4 weeks before enrollment; 6. Patients with mental or physical disabilities; 7. Suspect or have a history of alcohol and drug abuse; 8. Combined with other chemotherapy and traditional Chinese medicine anti-tumor therapy during the study administration period; 9. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progressive-free survival;Overall survival;Qualify of life; | — |
Countries
China
Contacts
Public ContactXiaojun Wu
Sun Yat-sen University Cancer Center
Outcome results
None listed